Exclusive Summary

• - Long off-patent with no meaningful IP barriers; ideal for rapid multi-country entry via Distribution.
• - Global hemophilia A incidence is ~1/5,000 male births with large underdiagnosis; LMIC demand and tenders are expanding.
• - Listed on the WHO Essential Medicines List and recommended by WFH as standard therapy for bleeding control and perioperative use.
• - Plasma-derived FVIII is typically 30–70% cheaper than recombinant/extended half-life products; the 200 IU vial reduces wastage in pediatrics and ED use.
• - USP/EP compliance supports registration and quality credibility; reliable cold chain and continuity of supply are key differentiators.